112 related articles for article (PubMed ID: 21801234)
41. [Chronic lymphatic leukemia and Hodgkin's disease].
Calvo Villas J; Ramírez Sánchez M; Sicilia Guillén F
Sangre (Barc); 1999 Oct; 44(5):393-4. PubMed ID: 10618924
[No Abstract] [Full Text] [Related]
42. Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab.
Gruber M; Fleiss K; Porpaczy E; Skrabs C; Hauswirth AW; Gaiger A; Vanura K; Heintel D; Shehata M; Einberger C; Thalhammer R; Fonatsch C; Jäger U
Ann Hematol; 2011 Oct; 90(10):1131-6. PubMed ID: 21617923
[TBL] [Abstract][Full Text] [Related]
43. Lack of HLA-DR expression in a patient with B-chronic lymphocytic leukemia.
Vartholomatos G; Kapsali E; Dokou E; Bourantas KL
J Exp Clin Cancer Res; 2001 Jun; 20(2):305-6. PubMed ID: 11484993
[TBL] [Abstract][Full Text] [Related]
44. Ofatumumab in previously untreated chronic lymphocytic leukaemia. No clear advantages when added to chlorambucil.
Prescrire Int; 2015 Nov; 24(165):262. PubMed ID: 26688893
[TBL] [Abstract][Full Text] [Related]
45. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
[TBL] [Abstract][Full Text] [Related]
46. Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia.
Del Poeta G; Ilaria Del Principe M; Buccisano F; Maurillo L; Niscola P; Venditti A; Amadori S
Expert Rev Anticancer Ther; 2006 Dec; 6(12):1787-800. PubMed ID: 17181492
[TBL] [Abstract][Full Text] [Related]
47. Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient.
Niscola P; Principe MI; Palombi M; Fratoni S; Piccioni D; Maurillo L; de Fabritiis P; Amadori S; Del Poeta G
Leuk Res; 2008 Feb; 32(2):363-5. PubMed ID: 17449094
[No Abstract] [Full Text] [Related]
48. Movement toward optimization of CLL therapy.
Rai KR; Barrientos JC
N Engl J Med; 2014 Mar; 370(12):1160-2. PubMed ID: 24645950
[No Abstract] [Full Text] [Related]
49. Chronic lymphocytic leukemia: something old, something new and something borrowed..
Perez K; Winer ES
Med Health R I; 2011 Jan; 94(1):15-8. PubMed ID: 21290989
[No Abstract] [Full Text] [Related]
50. Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1).
Robak T; Błoński JZ; Kasznicki M; Góra-Tybor J; Dmoszyńska A; Wojtaszko M; Skotnicki AB; Nowak W; Hellmann A; Lewandowski K; Zdziarska B; Konopka L; Ceglarek B; Dwilewicz-Trojaczek J; Boguradzki P; Kuliczkowski K; Sułek K; Warzocha K
Med Sci Monit; 2005 Oct; 11(10):PI71-9. PubMed ID: 16192912
[TBL] [Abstract][Full Text] [Related]
51. Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients.
D'Arena G; Capalbo S; Laurenti L; Del Poeta G; Nunziata G; Deaglio S; Spinosa G; Tarnani M; De Padua L; Califano C; Ferrara F; Cascavilla N
Eur J Haematol; 2010 Dec; 85(6):502-7. PubMed ID: 20846302
[TBL] [Abstract][Full Text] [Related]
52. A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
Hillmen P; Cohen DR; Cocks K; Pettitt A; Sayala HA; Rawstron AC; Kennedy DB; Fegan C; Milligan DW; Radford J; Mercieca J; Dearden C; Ezekwisili R; Smith AF; Brown J; Booth GA; Varghese AM; Pocock C;
Br J Haematol; 2011 Mar; 152(5):570-8. PubMed ID: 21231927
[TBL] [Abstract][Full Text] [Related]
53. [Immunological profile of lymphoid cells in patients with chronic lymphoid leukemia and immunological complications during the treatment with prednisolone and chlorambucil].
Lohins'kyĭ VO; Karol' IuS; Tsiapka OM; Vyhovs'ka IaI
Lik Sprava; 2009; (1-2):44-9. PubMed ID: 19953990
[TBL] [Abstract][Full Text] [Related]
54. Treatment of chronic lymphocytic leukemia: achieving minimal residual disease-negative status as a goal.
Montserrat E
J Clin Oncol; 2005 May; 23(13):2884-5. PubMed ID: 15738532
[No Abstract] [Full Text] [Related]
55. Combined use of alpha 2B-interferon, chlorambucil, and prednisone in the treatment of previously treated B-chronic lymphocytic leukemia patients.
Molica S
Am J Hematol; 1993 Mar; 42(3):334-5. PubMed ID: 8438908
[No Abstract] [Full Text] [Related]
56. Peliosis of the spleen and haemolytic anaemia.
Körner M; Gebbers JO
Histopathology; 2002 Aug; 41(2):179-80. PubMed ID: 12147103
[No Abstract] [Full Text] [Related]
57. Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era.
Mato A; Jahnke J; Li P; Mehra M; Ladage VP; Mahler M; Huntington S; Doshi JA
Haematologica; 2018 Oct; 103(10):e462-e465. PubMed ID: 29700170
[No Abstract] [Full Text] [Related]
58. Something fishy in the immunocompromised.
Sillito F; Cervi P; Skibinska M
Br J Haematol; 2011 Apr; 153(2):148. PubMed ID: 21401570
[No Abstract] [Full Text] [Related]
59. CLL progression after one cycle of FCR: Richter's transformation versus EBV-associated lympho-proliferation.
Jain P; Burger JA; Khoury JD
Am J Hematol; 2017 Oct; 92(10):1113-1114. PubMed ID: 28670739
[No Abstract] [Full Text] [Related]
60. How I Manage Chronic Lymphocytic Leukemia in 2014.
Alwbari A; Makhoul I
J Ark Med Soc; 2016 Feb; 112(10):187-8. PubMed ID: 26939472
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
